Treatment for women

Treatment for women features

• 

  HIV and TB in Practice for nurses: Pregnancy and TB/HIV

  This article explains how to prevent and treat TB in pregnant women to protect both mother and child....

  From:  HIV & AIDS treatment in practice

• 

  Point-of-care (POC) diagnostics are essential to achieving an AIDS-free generation and improving outcomes in HIV-exposed children

  This edition reviews recent evidence on point-of-care testing, on tests in development, and looks at experience of optimising performance of dried blood spot sampling....

  From:  HIV & AIDS treatment in practice

• 

  The generic generation

  In the next few years, some of the most widely used HIV drugs will come off patent in the UK. Gus Cairns asks: what are the...

  From:  HIV treatment update

• 

  Hillary Clinton pledges money for vulnerable minorities, reproductive rights, AIDS-free families

  US Secretary of State Hillary Clinton received a relatively warm reception yesterday at the 19th International AIDS Conference (AIDS 2012) in Washington DC, as she supported the...

  From:  News

• 

  HIV-positive women in clinical trials: A gap in the facts

  Sharon L Walmsley is one of a group of female physicians, experts and patient advocates who together set up Women for Positive Action, an organisation that campaigns...

  From:  HIV treatment update

• 

  Switching from efavirenz to nevirapine in women with higher CD4 counts

  This issue provides an overview of the risks and benefits, and real-life experiences, of switching from efavirenz to nevirapine in women with higher CD4 counts,...

  From:  HIV & AIDS treatment in practice

• 

  HIV treatment for mothers and children in Botswana: lessons from a dynamic programme

  Lessons from the Botswana national PMTCT programme on scaling up antiretroviral treatment for mothers and children....

  From:  HIV & AIDS treatment in practice

Treatment for women news from aidsmap

• Pregnancy does not increase risk of nevirapine side-effects

  Pregnancy does not increase the risk of nevirapine (Viramune) associated side-effects, according to the results of a systematic review and meta-analysis published in the online edition of AIDS. Investigators found that incidence of liver and skin toxicities – the major side-effects ...

  07 February 2013 | Michael Carter

• New fixed-dose combination pills measure up to Atripla - corrected version*

  Several studies, or updates of studies, comparing newer against older drug regimens were presented at the Eleventh International Congress on Drug Therapy in HIV Infection last week. Amongst them were the 48-week results from the STAR study, an open-label ...

  20 November 2012 | Gus Cairns

• Lack of understanding of treatment benefits may discourage women with HIV from having children – and could increase the risk of vertical transmission

  Two papers presented at the eleventh International Congress on Drug Therapy in HIV Infection this week in Glasgow suggest that some women with HIV may not have up-to-date information about vertical transmission (HIV being passed on from mother ...

  16 November 2012 | Gus Cairns

• Adverse birth outcomes more frequent in women exposed to ART during pregnancy, largest-ever study confirms

  Among HIV-infected women in Botswana, starting combination antiretroviral therapy during pregnancy was associated with an increased risk for adverse birth outcomes, including pre-term delivery, small for gestational age, stillbirth and neonatal death, researchers report in the largest study of birth ...

  30 October 2012 | Carole Leach-Lemens

• Late start for ART in pregnancy increases HIV transmission risk during breastfeeding period

  A high viral load at the time of starting treatment during pregnancy and a shorter time on antiretroviral therapy (ART) before delivery continued to place mothers at risk of passing on HIV during the breastfeeding period for ...

  27 September 2012 | Carole Leach-Lemens

• Global evidence of lower adherence to ARVs after giving birth

  Antiretroviral therapy (ART) adherence levels among pregnant women with HIV, in both high- and low-income countries, during pregnancy and especially after giving birth are significantly below what is recommended for viral suppression and prevention of drug resistance, according to a ...

  25 September 2012 | Carole Leach-Lemens

• ART for life cost effective for prevention of mother-to-child transmission in Uganda

  Combination antiretroviral therapy (ART) provided to all pregnant women with HIV who have CD4 cell counts under 350 cells/mm3 (World Health Organization Option B) in Uganda appears to be highly cost effective for the prevention of mother-to-child transmission (PMTCT), even ...

  18 September 2012 | Carole Leach-Lemens

• Hillary Clinton pledges money for vulnerable minorities, reproductive rights, AIDS-free families

  US Secretary of State Hillary Clinton received a relatively warm reception yesterday at the 19th International AIDS Conference (AIDS 2012) in Washington DC, as she supported the reproductive rights of women with HIV, unveiled a $37m programme to help ...

  24 July 2012 | Gus Cairns

• Co-administration of rifampicin and efavirenz does not reduce efavirenz concentrations or efficacy

  Standard dosing of efavirenz, that was not adjusted for patient weight, resulted in therapeutic efavirenz concentrations and excellent virological outcomes in patients coinfected with TB and HIV who were also taking a rifampicin-containing TB treatment, according to results from the ...

  24 July 2012 | Lesley Odendal

• Treatment with a ritonavir-boosted protease inhibitor during pregnancy increases risk of preterm delivery

  Antiretroviral therapy during pregnancy is associated with an increased risk of premature delivery, French researchers report in Clinical Infectious Diseases. The large study showed that treatment with a ritonavir-boosted protease inhibitor was especially associated with prematurity. “Our findings suggest a ...

  10 April 2012 | Michael Carter

More news

Treatment for women news selected from other sources

• HIV Drug Not Tied to Premature Births

  Pregnant HIV-infected women treated with a lopinavir/ritonavir (Kaletra)-based antiretroviral regimen are at no greater risk of delivering a preterm baby than similar pregnant women given an efavirenz (Sustiva)-based treatment, researchers said here.

  10 March 2013 | MedPage Today

• Are hospitals safe for women living with HIV?

  A human rights investigation conducted by the Namibia Women’s Health Network, Harvard Law School’s Human Rights Program, and Northeastern University School of Law found that women living with HIV are often mistreated in hospital settings. This report will be launched at the AIDS conference this week in Washington DC.

  25 July 2012 | 50.50

• How the Supreme Court's Obamacare Ruling Fails Poor Black Women With HIV

  By allowing states to choose whether or not they will expand Medicaid, the Supreme Court may have set back the fight against HIV/AIDS among poor women of color who desperately need treatment.

  03 July 2012 | ColorLines

• HIV Worsens Bone Loss After Menopause

  Compared to a control group, postmenopausal women with HIV infection had higher rates of bone loss and could well have a higher risk for fracture as they age, according to the researchers who conducted the study.

  03 January 2012 | Medscape (requires free registration)

• LATIN AMERICA: Female Condoms in Short Supply

  In spite of the growing spread of HIV/AIDS among women in Latin America and the Caribbean, the female condom, which could put them in charge of their health, is not readily available.

  30 November 2011 | Inter Press Service

• Studies in Post-Menopausal Women Reveal Potentially Higher Biological HIV Risk, as Well as Possible Tenofovir Concerns

  A little light from CROI 2011 has shone into the dark corners of research into aging women with HIV/AIDS. Two oral presentations compared HIV risk in pre-menopausal versus post-menopausal women.

  01 March 2011 | The BodyPro

• US: Best HIV Treatment Practices Among Women Receiving ADAP

  Women enrolled in AIDS Drug Assistance Programs (ADAPs) in California, New York and Illinois were more likely to be taking antiretroviral (ARV) medication according to treatment guidelines than women not on ADAPs. These findings, published in the March 1 issue of the Journal of Acquired Immune Deficiency Syndromes, hold up even when the analysis includes women with public or private health insurance.

  16 February 2011 | AIDSMeds

• Registry Sees No Increased Overall Birth Defect Risk With First-Trimester Antiretrovirals

  Ongoing international reporting to the Antiretroviral Pregnancy Registry discerned no greater risk of birth defects among women taking antiretrovirals during the first trimester than among women taking antiretrovirals later in pregnancy.

  14 January 2011 | NATAP

• Program Reduces Cervical Cancer Deaths Among HIV-infected Women In Zambia

  A new study undertaken in Zambia shows that, using setting-appropriate human resources and technology, morbidity and mortality from cervical cancer among HIV-infected women can be reduced...

  15 December 2010 | HIV / AIDS News From Medical News Today

• American College of Obstetricians and Gynecologists Issues Guidelines on Care for HIV-Infected Women

  The guidelines cover the recommended health screenings, counseling, and routine gynecologic care for women with HIV/AIDS.

  23 November 2010 | Medscape

More news